Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 7, 2004, Pages 737-742

  Dutta, Sandeep ^a,b   Reed, Ronald C ^a   Cavanaugh, John H ^a  

^a ABBOTT LABORATORIES   (United States)

^b Building AP13A ^*  (United States)

Author keywords

Modified release; Pharmacokinetics; Sustained release; Valproate

Indexed keywords

VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CORRELATION COEFFICIENT; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DOSE REGIMEN; DRUG FORMULATION; EPILEPSY; EVALUATION; EXTENDED RELEASE TABLET; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SUSTAINED RELEASE PREPARATION;

ADOLESCENT; ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; VALPROIC ACID;

EID: 2942638198     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266782     Document Type: Article

References (10)

1. Depakote® tablets product information. Divalproex sodium delayed-release tablets. Chicago: Abbott Laboratories, 2003.
2. Gugler R, von Unruh GE: Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980;5:67-83.
3. Hussein Z, Mukherjee D, Lamm J, Cavanaugh JH, Granneman GR: Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J Clin Pharmacol 1994;34:754-759.
4. Reed RC, Dutta S, Lamm J, Chun AHC, Zhang Y, Cavanaugh JH: Bioavailability and effect of food on multiple-dose extended-release divalproex sodium. Biopharm Drug Dispos; in press.
5. Depakote® ER tablets product information. Divalproex sodium extended-release tablets. Chicago: Abbott Laboratories, 2003.
6. Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW: Comparison of the bioavailability of unequal doses of divalproex sodium extended-release (ER) formulation relative to divalproex sodium delayed-release (DR) formulation in healthy volunteers. Epilepsy Res 2003;49(1):1-10.
7. Sommerville KW, Dutta S, Biton V, Zhang Y, Cloyd JC, Uthman B: Bioavailability of a divalproex sodium extended-release formulation versus divalproex sodium delayed-release tablet formulation in adult patients on enzyme-inducing AEDs. Clin Drug Invest 2003;23(10):661-670.
8. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
9. Dutta S, Reed RC: Divalproex to divalproex-ER conversion. Clin Drug Invest; in press.
10. Qiu Y, Garren J, Samara E, Cao G, Abraham C, Cheskin HS, et al: Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method. J Pharm Sci 2003;92(11):2317-2325.